Chemical corrector treatment ameliorates increased seizure susceptibility in a mouse model of familial epilepsy

Nature Medicine

Volumn 21, Issue 1, 2015, Pages 19-26

  Yokoi, Norihiko ^a,b   Fukata, Yuko ^a,b   Kase, Daisuke ^a   Miyazaki, Taisuke ^c   Jaegle, Martine ^d   Ohkawa, Toshika ^a,b   Takahashi, Naoki ^a   Iwanari, Hiroko ^e   Mochizuki, Yasuhiro ^e,f   Hamakubo, Takao ^e   Imoto, Keiji ^a,b   Meijer, Dies ^d,g   Watanabe, Masahiko ^c,h   Fukata, Masaki ^a,b  

^a NATIONAL INSTITUTE FOR PHYSIOLOGICAL SCIENCES   (Japan)

^b GRADUATE UNIVERSITY FOR ADVANCED STUDIES   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF TOKYO   (Japan)

^f Komaba Open Lab Grad Sch F   (Japan)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; LIGAND; MUTANT PROTEIN; 4-PHENYLBUTYRIC ACID; ADAM PROTEIN; ADAM22 PROTEIN, MOUSE; ARYLBUTYRIC ACID DERIVATIVE; LGI1 PROTEIN, HUMAN; NERVE PROTEIN; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL DOMINANT LATERAL TEMPORAL LOBE EPILEPSY; CELL FRACTIONATION; CELL MIGRATION; CELLULAR DISTRIBUTION; CONFOCAL LASER MICROSCOPY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; FEMALE; GENE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LATERAL TEMPORAL LOBE EPILEPSY; LGI1 GENE; LOSS OF FUNCTION MUTATION; MALE; MISSENSE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN SECRETION; RECEPTOR BINDING; SEIZURE SUSCEPTIBILITY; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; EPILEPSY, FRONTAL LOBE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; SEIZURES; SLEEP DISORDERS;

MUS;

ADAM PROTEINS; ANIMALS; DISEASE MODELS, ANIMAL; EPILEPSY, FRONTAL LOBE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; MUTATION; NERVE TISSUE PROTEINS; PHENYLBUTYRATES; PROTEIN FOLDING; PROTEINS; SEIZURES; SLEEP DISORDERS;

EID: 84925284510     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3759     Document Type: Article

References (45)

1. Gu, W., Brodtkorb, E. & Steinlein, O.K. LGI1 is mutated in familial temporal lobe epilepsy characterized by aphasic seizures. Ann. Neurol. 52, 364-367 (2002).
2. Kalachikov, S. et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat. Genet. 30, 335-341 (2002).
3. Morante-Redolat, J.M. et al. Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. Hum. Mol. Genet. 11, 1119-1128 (2002).
4. Irani, S.R. et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 133, 2734-2748 (2010).
5. Lai, M. et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 9, 776-785 (2010).
6. Ohkawa, T. et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J. Neurosci. 33, 18161-18174 (2013).
7. Chabrol, E. et al. Electroclinical characterization of epileptic seizures in leucine-rich, glioma-inactivated 1-deficient mice. Brain 133, 2749-2762 (2010).
8. Fukata, Y. et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc. Natl. Acad. Sci. USA 107, 3799-3804 (2010).
9. Yu, Y.E. et al. Lgi1 null mutant mice exhibit myoclonic seizures and CA1 neuronal hyperexcitability. Hum. Mol. Genet. 19, 1702-1711 (2010).
10. Schulte, U. et al. The epilepsy-linked Lgi1 protein assembles into presynaptic Kv1 channels and inhibits inactivation by Kvbeta1. Neuron 49, 697-706 (2006).
11. Fukata, Y. et al. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science 313, 1792-1795 (2006).
12. Sagane, K. et al. Ataxia and peripheral nerve hypomyelination in ADAM22-deficient mice. BMC Neurosci. 6, 33 (2005).
13. Owuor, K. et al. LGI1-associated epilepsy through altered ADAM23-dependent neuronal morphology. Mol. Cell. Neurosci. 42, 448-457 (2009).
14. Zhou, Y.D. et al. Arrested maturation of excitatory synapses in autosomal dominant lateral temporal lobe epilepsy. Nat. Med. 15, 1208-1214 (2009).
15. Nobile, C. et al. LGI1 mutations in autosomal dominant and sporadic lateral temporal epilepsy. Hum. Mutat. 30, 530-536 (2009).
16. Senechal, K.R., Thaller, C. & Noebels, J.L. ADPEAF mutations reduce levels of secreted LGI1, a putative tumor suppressor protein linked to epilepsy. Hum. Mol. Genet. 14, 1613-1620 (2005).
17. Striano, P. et al. Familial temporal lobe epilepsy with psychic auras associated with a novel LGI1 mutation. Neurology 76, 1173-1176 (2011).
18. Ho, Y.Y., Ionita-Laza, I. & Ottman, R. Domain-dependent clustering and genotype-phenotype analysis of LGI1 mutations in ADPEAF. Neurology 78, 563-568 (2012).
19. Soldà, T., Galli, C., Kaufman, R.J. & Molinari, M. Substrate-specific requirements for UGT1-dependent release from calnexin. Mol. Cell 27, 238-249 (2007).
20. Honoré, B. The rapidly expanding CREC protein family: members, localization, function, and role in disease. BioEssays 31, 262-277 (2009).
21. Sirerol-Piquer, M.S. et al. The epilepsy gene LGI1 encodes a secreted glycoprotein that binds to the cell surface. Hum. Mol. Genet. 15, 3436-3445 (2006).
22. Ozkaynak, E. et al. Adam22 is a major neuronal receptor for Lgi4-mediated Schwann cell signaling. J. Neurosci. 30, 3857-3864 (2010).
23. Kegel, L. et al. Functional phylogenetic analysis of LGI proteins identifies an interaction motif crucial for myelination. Development 141, 1749-1756 (2014).
24. Okiyoneda, T. & Lukacs, G.L. Fixing cystic fibrosis by correcting CFTR domain assembly. J. Cell Biol. 199, 199-204 (2012).
25. Ward, C.L., Omura, S. & Kopito, R.R. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83, 121-127 (1995).
26. Rubenstein, R.C., Egan, M.E. & Zeitlin, P.L. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J. Clin. Invest. 100, 2457-2465 (1997).
27. Hutt, D.M. et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat. Chem. Biol. 6, 25-33 (2010).
28. Mu, T.W. et al. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134, 769-781 (2008).
29. Ozcan, U. et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137-1140 (2006).
30. Kopito, R.R. & Ron, D. Conformational disease. Nat. Cell Biol. 2, E207-E209 (2000).
31. Zode, G.S. et al. Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma. J. Clin. Invest. 121, 3542-3553 (2011).
32. Lu, J. et al. Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc. Natl. Acad. Sci. USA 108, 21200-21205 (2011).
33. Yang, C., Huntoon, K., Ksendzovsky, A., Zhuang, Z. & Lonser, R.R. Proteostasis modulators prolong missense VHL protein activity and halt tumor progression. Cell Reports 3, 52-59 (2013).
34. Gallagher, M.J., Ding, L., Maheshwari, A. & Macdonald, R.L. The GABAA receptor alpha1 subunit epilepsy mutation A322D inhibits transmembrane helix formation and causes proteasomal degradation. Proc. Natl. Acad. Sci. USA 104, 12999-13004 (2007).
35. Iannitti, T. & Palmieri, B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R D. 11, 227-249 (2011).
36. Pedemonte, N. et al. Phenylglycine and sulfonamide correctors of defective F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol. Pharmacol. 67, 1797-1807 (2005).
37. Van Goor, F. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. USA 106, 18825-18830 (2009).
38. Rosanoff, M.J. & Ottman, R. Penetrance of LGI1 mutations in autosomal dominant partial epilepsy with auditory features. Neurology 71, 567-571 (2008).
39. Yamazaki, M. et al. TARPs gamma-2 and gamma-7 are essential for AMPA receptor expression in the cerebellum. Eur. J. Neurosci. 31, 2204-2220 (2010).
40. Masuda, K. et al. A combinatorial G protein-coupled receptor reconstitution system on budded baculovirus. Evidence for G alpha(i) and G alpha(o) coupling to a human leukotriene B4 receptor. J. Biol. Chem. 278, 24552-24562 (2003).
41. Saitoh, R. et al. Viral envelope protein gp64 transgenic mouse facilitates the generation of monoclonal antibodies against exogenous membrane proteins displayed on baculovirus. J. Immunol. Methods 322, 104-117 (2007).
42. Lüthi, A. et al. Endogenous serine protease inhibitor modulates epileptic activity and hippocampal long-term potentiation. J. Neurosci. 17, 4688-4699 (1997).
43. Watanabe, M. et al. Selective scarcity of NMDA receptor channel subunits in the stratum lucidum (mossy fibre-recipient layer) of the mouse hippocampal CA3 subfield. Eur. J. Neurosci. 10, 478-487 (1998).
44. Noritake, J. et al. Mobile DHHC palmitoylating enzyme mediates activity-sensitive synaptic targeting of PSD-95. J. Cell Biol. 186, 147-160 (2009).
45. Faul, F., Erdfelder, E., Lang, A.G. & Buchner, A. G∗Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 39, 175-191 (2007).